Study Limitations
• The underlying data from which the sample was drawn are not static and represent patient records from prescribers currently participating in the transcription service. New prescribers may join or leave the service at any time during the study period.
• Filgrastim-sndz was available for less than 2 months of the study period, thus limiting the observation timeframe.
-Next year's follow-up data will be more revealing of uptake.
• It is not clear how the 6-month delay to launch after FDA approval has affected market uptake of filgrastim-sndz.
• Anticipation of the impending availability of filgrastim-sndz, the first official biosimilar in the USA, may have dampened prescriptions for tbo-filgrastim.
• Payer coverage and formulary policy in California, both in commercial plans and in Medicare, entailed additional reauthorisation requirements for use of tbo-filgrastim not needed for filgrastim. -In European markets, discounting of filgrastim biosimilars has ranged from 10-30%.
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Methods
• Physician records were extracted from RealHealthData (RHD), a US medical transcription database ( Figure 2 ).
-Data are available within 72 hours of each visit to a participating provider, enabling uptake of newly launched products to be observed with a limited lag time. -Records are in the form of physician-reported notes for office visits that document real-time data, without concern for recall or bias. -The data provide context about the physician's intent-to-treat at the time of the visit. • Data were scanned over the study period from 1 November 2013 to 13
October 2015 and compared with online market reports.
• Records were searched, with counts tabulated, for mention of filgrastim agents as follows: -Tbo-filgrastim: "tbo-filgrastim," "Granix," or "Neutroval" -Filgrastim-sndz: "filgrastim-sndz," "Zarxio" or "Zarzio" -Filgrastim: "filgrastim" or "Neupogen" -Pegfilgrastim: pegfilgrastim" or "Neulasta." • Although RHD includes provider-reported data from all 50 states, approximately 86% of the available reports mentioning use of a G-CSF were from oncologists in California.
Results

Figure 1. Timeline of Filgrastim Approval and Launch
• Counts of mentions of G-CSF by product name and by number of unique patients and prescribers are presented in Table 2 .
• Tbo-filgrastim was reported 6 times, for 5 unique patients, with all mentions referred to as "Granix".
• 59 Providers reported use of filgrastim, while only 4 reported use of tbofilgrastim.
-The 4 tbo-filgrastim providers were all located in the North of California.
• Based on physician reports, tbo-filgrastim was utilised as follows ( Figure 3) : -Tbo-filgrastim, a short-acting G-CSF, was prescribed as an interim treatment for 2 patients undergoing chemotherapy who normally received pegfilgrastim, a long-acting G-CSF. › An example of patient chart notes showing this use is provided in a supplemental figure (Exhibit 2). -1 Patient, who had no evidence of receiving chemotherapy, reported taking tbo-filgrastim, as needed, for neutropenia symptoms -Prophylactic tbo-filgrastim was prescribed in 3 visits for 2 chemotherapy patients -Only 2 of the 4 patients undergoing chemotherapy received tbo-filgrastim as their primary G-CSF therapy.
• No mentions of filgrastim-sndz were identified. 
Discussion
• Data from this small sample show that tbo-filgrastim is mentioned in slightly more than 1% of provider records that report a short-acting G-CSF.
-In comparison, tbo-filgrastim is reported to have captured approximately 15-16% of the overall market for short-acting G-CSF in the USA based on IMS sales data.
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• There may be several reasons why uptake of tbo-filgrastim in the study sample was much lower than the reported market share: -The sample was small and highly localised, and therefore is not representative of US prescribing patterns -Differences between sales data and utilisation data -Providers may have had service contracts in place for filgrastim that could delay adoption of competing agents.
Conclusions
• Among nearly 3000 records reporting a G-CSF in this snapshot of primarily Californian oncologists, uptake of subsequent filgrastim agents was limited and highly concentrated in 1 region in the North of California.
-Only 6 mentions of tbo-filgrastim were noted in the 18 months since launch.
-No mentions of filgrastim-sndz were identified in the more than 2 months since launch.
• As educational initiatives increase physician awareness of alternate G-CSFs, existing supply contracts with originator manufacturers expire, and the length of time on the market increases, uptake of new filgrastim agents in the USA is expected to accelerate. To view an animated, descriptive timeline, scan the QR Code here
Objective
• The objective of this study was to assess the uptake of 'biosimilar' filgrastim by identifying physician documentation referencing use of tbo-filgrastim and filgrastim-sndz in the USA during patient office visits.
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